VSTM vs. EPZM, AGEN, XOMA, VNDA, EBS, CDXS, ACHV, RIGL, RGLS, and SGMO
Should you be buying Verastem stock or one of its competitors? The main competitors of Verastem include Epizyme (EPZM), Agenus (AGEN), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Emergent BioSolutions (EBS), Codexis (CDXS), Achieve Life Sciences (ACHV), Rigel Pharmaceuticals (RIGL), Regulus Therapeutics (RGLS), and Sangamo Therapeutics (SGMO). These companies are all part of the "medical" sector.
Epizyme (NASDAQ:EPZM) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment, community ranking and profitability.
Verastem has lower revenue, but higher earnings than Epizyme. Verastem is trading at a lower price-to-earnings ratio than Epizyme, indicating that it is currently the more affordable of the two stocks.
Epizyme has a beta of -0.41, suggesting that its share price is 141% less volatile than the S&P 500. Comparatively, Verastem has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500.
76.5% of Epizyme shares are owned by institutional investors. Comparatively, 88.4% of Verastem shares are owned by institutional investors. 23.4% of Epizyme shares are owned by insiders. Comparatively, 2.2% of Verastem shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Verastem had 12 more articles in the media than Epizyme. MarketBeat recorded 12 mentions for Verastem and 0 mentions for Epizyme. Verastem's average media sentiment score of 0.22 beat Epizyme's score of -0.05 indicating that Epizyme is being referred to more favorably in the media.
Verastem has a net margin of 0.00% compared to Verastem's net margin of -391.90%. Epizyme's return on equity of -157.95% beat Verastem's return on equity.
Verastem has a consensus target price of $25.69, suggesting a potential upside of 548.67%. Given Epizyme's higher probable upside, analysts clearly believe Verastem is more favorable than Epizyme.
Verastem received 121 more outperform votes than Epizyme when rated by MarketBeat users. Likewise, 65.28% of users gave Verastem an outperform vote while only 62.27% of users gave Epizyme an outperform vote.
Summary
Verastem beats Epizyme on 12 of the 17 factors compared between the two stocks.
Get Verastem News Delivered to You Automatically
Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VSTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verastem Competitors List
Related Companies and Tools
